Rabbani S A, Mitchell J, Roy D R, Hendy G N, Goltzman D
Department of Physiology, McGill University, Montreal, Quebec, Canada.
Endocrinology. 1988 Dec;123(6):2709-16. doi: 10.1210/endo-123-6-2709.
We compared the bioactivities of a synthetic truncated NH2-terminal fragment of the human (h) PTH-like peptide (PLP) associated with malignancies [hPLP-(3-34)], an intact NH2-terminal fragment [hPLP-(1-34)], and an NH2-terminal fragment of PTH [hPTH-(1-34)]. Although hPLP-(1-34) was less potent than hPTH-(1-34) in stimulating adenylate cyclase in rat renal membranes, hPLP-(1-34) and hPTH-(1-34) were equipotent in stimulating adenylate cyclase in OK renal cells as well as in UMR 108 osteosarcoma cells in vitro. In osteosarcoma cells, each of these peptides could desensitize adenylate cyclase responses to itself and to the other peptide, but could not reduce stimulation by prostaglandin E2. Renal membranes of vitamin D-deficient rats with secondary hyperparathyroidism had a reduced PLP-stimulated as well as PTH-stimulated adenylate cyclase response. The truncated analog hPLP-(3-34) was only a weak partial agonist and an antagonist in vitro, produced equivalent inhibition of hPLP-(1-34) and hPTH-(1-34) in renal and osseous cells, and could not desensitize agonist responses. In thyroparathyroidectomized rats in vivo, hPLP-(1-34) and hPTH-(1-34) increased cAMP excretion, enhanced phosphaturia, maintained plasma calcium, and reduced calciuria. Equimolar concentrations of hPLP-(3-34) produced no increases above control levels; however, high concentrations of this peptide mimicked PTH actions on renal and plasma ion handling while modestly augmenting cAMP excretion. These results demonstrate the importance of the first two residues of PLP for bioactivity, indicate that PLP and PTH interact at common receptor sites in vivo as well as in vitro, suggest that PLP may not be less potent than PTH in renal target cells, and indicate that the net result of interaction of these peptides with their common receptor in target tissues may reflect both activation and desensitization of receptor-mediated events.
我们比较了与恶性肿瘤相关的人(h)甲状旁腺激素样肽(PLP)的合成截短型NH2末端片段[hPLP-(3-34)]、完整的NH2末端片段[hPLP-(1-34)]以及甲状旁腺激素的NH2末端片段[hPTH-(1-34)]的生物活性。尽管hPLP-(1-34)在刺激大鼠肾膜中的腺苷酸环化酶方面比hPTH-(1-34)效力更低,但hPLP-(1-34)和hPTH-(1-34)在体外刺激OK肾细胞以及UMR 108骨肉瘤细胞中的腺苷酸环化酶时效力相当。在骨肉瘤细胞中,这些肽中的每一种都能使腺苷酸环化酶对自身和另一种肽的反应脱敏,但不能降低前列腺素E2的刺激作用。患有继发性甲状旁腺功能亢进的维生素D缺乏大鼠的肾膜对PLP刺激以及PTH刺激的腺苷酸环化酶反应降低。截短型类似物hPLP-(3-34)在体外只是一种弱的部分激动剂和拮抗剂,在肾细胞和骨细胞中对hPLP-(1-34)和hPTH-(1-34)产生同等程度的抑制,并且不能使激动剂反应脱敏。在体内甲状旁腺切除的大鼠中,hPLP-(1-34)和hPTH-(1-34)增加了环磷酸腺苷(cAMP)排泄,增强了尿磷排泄,维持了血钙水平,并减少了尿钙排泄。等摩尔浓度的hPLP-(3-34)未使水平升高超过对照水平;然而,高浓度的这种肽在模拟PTH对肾和血浆离子处理的作用时,适度增加了cAMP排泄。这些结果证明了PLP前两个残基对生物活性的重要性,表明PLP和PTH在体内和体外的共同受体位点相互作用,提示PLP在肾靶细胞中的效力可能不低于PTH,并表明这些肽与其在靶组织中的共同受体相互作用的最终结果可能反映受体介导事件的激活和脱敏。